Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026)
Olema Pharmaceuticals' (OLMA) quarterly Income from Continuing Operations came in at 145101000.0 in Q1 2026, down 358.18% year-on-year from 56201503.97 in Q1 2025, and down 214.93% on a QoQ basis from 46074000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Income from Continuing Operations data on file, last reported at 145101000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 358.18% year-over-year to 145101000.0 in Q1 2026; TTM through Mar 2026 was 279470000.0, a 31.89% decrease from a year earlier, with the FY2025 full-year figure at 398134000.0, down 190.41% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 145101000.0, down from 46074000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for OLMA reached as high as 25797000.0 in Q3 2022 and fell as low as 145101000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 50755352.94 across 5 years, with a median of 42541000.0 in 2025.
- Across the five-year window, Income from Continuing Operations jumped 78.22% in 2022 and sank 358.18% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 26569000.0 in 2022, then decreased by 2.1% to 27128000.0 in 2023, then declined by 24.52% to 33780000.0 in 2024, then plunged by 36.39% to 46074000.0 in 2025, then plunged by 214.93% to 145101000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 145101000.0 in Q1 2026, 46074000.0 in Q4 2025, and 42541000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Olema Pharmaceuticals | 1.21 Bn | 1.21 Bn | - | -145.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.10 Mn |
| Dec 31, 2025 | -46.07 Mn |
| Sep 30, 2025 | -42.54 Mn |
| Jun 30, 2025 | -45.75 Mn |
| Mar 31, 2025 | -31.67 Mn |
| Dec 31, 2024 | -33.78 Mn |
| Sep 30, 2024 | -78.93 Mn |
| Jun 30, 2024 | -67.53 Mn |
| Mar 31, 2024 | -71.72 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -75.36 Mn |
| Jun 30, 2023 | -51.62 Mn |
| Mar 31, 2023 | -30.33 Mn |
| Dec 31, 2022 | -26.57 Mn |
| Sep 30, 2022 | -25.80 Mn |
| Jun 30, 2022 | -36.40 Mn |
| Mar 31, 2022 | -26.55 Mn |
| Dec 31, 2021 | -42.72 Mn |
| Sep 30, 2021 | -89.42 Mn |
| Jun 30, 2021 | -97.17 Mn |